Diabetes Care Devices Market – By Product, By End Use – Global Forecast, 2024 – 2032

Diabetes Care Devices Market Size

The global diabetes care devices market size was valued at around USD 45.1 billion in 2023 and is estimated to grow at 11.4% CAGR from 2024 to 2032. Diabetes care devices refer to a range of medical tools designed to monitor, manage, and treat diabetes. These devices include blood glucose meters, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, syringes, and lancets, each serving a critical role in helping individuals maintain optimal blood sugar levels and manage insulin therapy effectively.
 

The growing prevalence of diabetes across the world is the primary factor propelling the diabetes care devices market growth. For instance, according to the World Health Organization (WHO), in 2024, approximately 422 million people worldwide have diabetes, with the majority residing in low- and middle-income countries. Additionally, 1.5 million deaths are directly attributed to diabetes each year. This increasing incidence of diabetes is anticipated to fuel demand for effective management solutions, including continuous glucose monitoring, and insulin delivery devices. Consequently, this demand is likely to drive advancements in diabetes care devices to improve patient outcomes and enhance disease management.
 

Moreover, the market growth is driven by rising technological advancements in diabetes care devices and increasing investments by public and private organizations for diabetes care.
 

Diabetes Care Devices Market Trends

Rising technological advancements in diabetes care devices are a key driver for the market. These advancements have revolutionized the management and treatment of diabetes, offering patients and healthcare providers innovative tools to monitor glucose levels, administer insulin, and improve overall diabetes care.
 

• The development of non-invasive diabetes care devices is increasing the popularity of the market. Various companies are focusing on developing devices that are painless, cost-effective, highly accurate and offer reliable results to the diabetic patients.
   
• For instance, the G7, manufactured by Dexcom, represents their most precise sensor to date. This device is suitable for individuals with type 1, type 2, or gestational diabetes. Notably, the sensor is 60% smaller than its predecessor, the G6. It is typically worn on the upper arm, although children aged 2-6 should wear it on the upper buttocks. The G7 provides real-time glucose data directly to smartphone or smartwatch, eliminating the need for fingerstick tests.
   
• Moreover, the integration of digital software with diabetes care devices aids in better monitoring and control of blood sugar levels. For instance, in June 2022, LifeScan stated that the data obtained from the Journal of Diabetes Technology and Therapeutics (DTT) offers real-time evidence of a better glucose concentration level in diabetic patients using glucometers with mobile diabetes management application that is connected to bluetooth. Thus, aforementioned factors are propelling the market growth.
   

Diabetes Care Devices Market Analysis

Based on product, the market is segmented into blood glucose monitoring devices, insulin delivery devices, syringes, and other insulin delivery devices. Further, blood glucose monitoring devices is segmented for self-monitoring blood glucose meters, continuous glucose monitors, testing strips, and lancets. The blood glucose monitoring devices segment dominated the market in 2023, accounting for a market share of 58.4% and a CAGR of 11.6%.
 

• Blood glucose monitoring devices are essential tools for individuals with diabetes to track their blood sugar levels, providing critical information that empowers patients to make informed decisions about diet, exercise, and insulin dosing.
   
• Given the need for continuous monitoring to avoid complications such as hypoglycemia and hyperglycemia, these devices deliver real-time data, allowing users to maintain better control over their glucose levels throughout the day.
   
• The global prevalence of diabetes continues to rise, driving an increased demand for these monitoring devices. For instance, Scotland, such as many other countries, has experienced an upward trend in diabetes diagnoses. The Scottish Diabetes Survey highlights this growth across various age groups for both type 1 and type 2 diabetes cases.
   
• These combined factors are accelerating growth in the blood glucose monitoring devices market.
   

Based on end use, the diabetes care devices market is segmented into hospital, ambulatory surgical centres, diagnostic centres, homecare, and other end users. The hospital dominated the market with a substantial 24% market share in 2023 and is estimated for sizable growth ahead.
 

• Hospitals offer comprehensive diabetes care services, including diagnosis, treatment, monitoring, and management. They require a wide range of devices such as glucose meters, insulin pumps, continuous glucose monitoring (CGM) systems, and insulin pens. Hospitals integrate these devices into their care pathways, making them a central part of their diabetes treatment protocols.
   
• Furthermore, the increasing number of hospitals is a significant driver for the market. For instance, there were 6,093 hospitals in the U.S. in 2023. This growing number increases the adoption trends for diabetes care devices.
   
• Hospitals often have specialized paediatric endocrinologists or diabetes department that are well-equipped to diagnose and manage diabetes in children and adolescents.  Thus, increasing number of diabetes cases in youth allows them to seek hospitals because of the availability of these specialized healthcare providers. Therefore, these factors are expected to augment segmental growth.
   

The U.S. dominated the North American diabetes care devices market with the largest revenue of USD 15.4 billion in 2023.
 

• The U.S. has one of the highest healthcare expenditures globally. This contributes to the investment in advanced diabetes care technologies, contributing to market growth.
   
• For instance, according to a report published by Health Affairs, the U.S. healthcare expenditure in 2023 was about USD 4.7 trillion, accounting for 18% of the national economy. This expenditure translates to nearly double the average spending of similarly wealthy countries on a per capita basis. Thus, driving the adoption of diabetes care devices.
   
• Further, the Food and Drug Administration (FDA) provides a streamlined regulatory process for the approval of new diabetes care devices, fostering a conducive environment for innovation and market entry.
   

The diabetes care devices market in the UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK is known for its cutting-edge research in diabetes care and management, supported by leading universities and research institutions. Collaborations between academia and industry drive innovations in diabetes care devices, enhancing their effectiveness and user experience.
   
• Increased public awareness of diabetes and its management has led to greater demand for diabetes care devices. Educational initiatives aimed at healthcare professionals and patients contribute to better understanding and utilization of these technologies.
   

Japan's diabetes care devices market is anticipated to witness lucrative growth between 2024 and 2032.
 

• Japan has one of the world’s oldest populations, leading to a higher prevalence of chronic diseases, including diabetes. This demographic trend drives demand for diabetes care devices that help manage health conditions effectively.
   
• Japan is known for its technological advancements and innovation in medical devices. The country invests heavily in research and development, leading to the creation of cutting-edge diabetes care devices, including advanced glucose monitoring systems and insulin delivery technologies.
   

The diabetes care devices market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The Saudi government is actively investing in healthcare infrastructure as part of its Vision 2030 plan, which aims to improve the overall health of the population. This includes enhancing access to diabetes care devices and promoting preventive health measures.
   
• Investment in research and development, particularly in biotechnology and medical devices, supports the creation of innovative diabetes care solutions tailored to the local population’s needs.
   

Diabetes Care Devices Market Share

The market is highly competitive, featuring a blend of leading global manufacturers and smaller to medium-sized enterprises competing for market share. A critical aspect of market strategy involves the continuous introduction of innovative technologies and devices, such as advanced glucose monitoring systems and smart insulin delivery solutions. Prominent industry leaders significantly influence the market, often driving advancements through substantial investments in research and development.
 

Additionally, mergers, acquisitions, and strategic partnerships are essential for consolidating market positions and expanding global reach in response to evolving healthcare practices and regulatory frameworks. The growing emphasis on personalized diabetes management, improved patient outcomes, and enhanced user experience continues to shape the competitive landscape, influencing product offerings and healthcare providers' trust in diabetes care device.
 

Diabetes Care Devices Market Companies

Some of the eminent market participants operating in the diabetes care devices industry include:

• Abbott Laboratories
• ARKRAY
• Ascensia Diabetes Care Holding
• B. Braun Melsungen
• Becton, Dickinson and Company
• Bionime Corporation
• DarioHealth Corp.
• Dexcom
• Dr. Reddy’s Laboratories
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Insulet Corporation
• Medtronic
• Nova Biomedical
• Novo Nordisk
• Pendiq
• Platinum Equity Advisors
• Sanofi
• Sinocare
• Tandem Diabetes Care
• Ypsomed Holding
   

Diabetes Care Devices Industry News:

• In March 2024, Dexcom introduced its newest CGM system, Dexcom ONE+, in Ireland. Dexcom ONE+ utilizes Dexcom's top-tier and highly accurate sensor design. This product launch will bolster the company's product portfolio in the Irish market and is expected to boost the company's revenue.
   
• In June 2022, Abbott announced the launch of a bio wearable that help in continuous blood glucose and ketone monitoring in a single sensor. This move helped the company to enhance its product offerings.
   

The diabetes care devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Blood glucose monitoring devices 
  • Self-monitoring blood glucose meters
  • Continuous glucose monitors
  • Testing strips
  • Lancets 
• Insulin delivery devices
  • Insulin pumps
    • Tubed pumps
    • Tubeless pumps
  • Pens
    • Reusable
    • Disposable
  • Pen needles
    • Standard
    • Safety
  • Syringes
  • Other insulin delivery devices

Market, By End Use

• Hospital
• Ambulatory surgical centres         
• Diagnostic centres
• Homecare
• Other end users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Sweden
  • Belgium
  • Denmark
  • Finland
  • Norway
  • Lithuania
  • Latvia
  • Estonia 
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea 
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru 
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Egypt
  • Israel
  • Kuwait
  • Qatar